Imiglucerase proszek do przyg. konc. do sporz. roztw. do inf. (400 j.) | Eliglustat 84 mg | Awalglukozydaza alfa 100 mg proszek do przygotowania koncentratu do sporządzania roztworu do infuzji, fiolka 10 ml | Interferon beta - 1a roztw. do wstrz. 30 µg - 6 mln j.m. | Interferon beta - 1a roztw. do wstrz. a 132 µg | Interferon beta - 1b proszek i rozp. do sporz. roztw. do wstrz. 250 µg/ml | Fingolimod kaps. twarde 0,5 mg | Natalizumab 150 mg/1ml | Natalizumab konc. do sporz. roztw. do inf. 20 mg/ml | Peginterferon beta-1a roztw. do wstrz. 63 µg/0,5 ml; 94 µg/0,5 ml oraz Peginterferon beta-1a roztw. do wstrz. 125 µg/0,5 ml | Teriflunomidum 14 mg | Dimethyl fumarate 240 mg i Dimethyl fumarate 120 mg | Kladrybina 10 mg | Ocrelizumabum 30 mg/ml koncentrat do sporządzania roztworu do infuzji oraz Ocrelizumabum 40 mg/ml roztwór do wstrzykiwań | Glatiramer acetate roztw. do wstrz. 40 mg/ml | Ozanimodum 230 mcg + 460 mcg oraz Ozanimodum 920 mcg | Ponesimodum opakowanie przeznaczone do rozpoczynania leczenia (2x2mg+2x3mg+2x4mg+1x5mg+1x6mg+1x7mg+1x8mg +1x9mg+3x10mg) oraz Ponesimodum 20 mg | Ofatumumabum roztwór do wstrzykiwań 20 mg/ 0,4 ml we wstrzykiwaczu półautomatycznym | Siponimodum 0,25 mg, Siponimodum 1 mg oraz Siponimodum 2 mg | Satralizumab 120 mg roztwór do wstrzykiwań w ampułko-strzykawce | Ublituximab 150 mg/6 ml | Betaine proszek doustny (1 g) | Abobotulinumtoxin A 500 j.m. oraz Abobotulinumtoxin A 300 j.m. | Onabotulinumtoxin A 100 j.m | Incobotulinumtoxin A 100 j.m. | Agalsidasum beta proszek do przygotowania koncentratu do sporządzania roztworu do infuzji 5 mg oraz Agalsidasum beta proszek do przygotowania koncentratu do sporządzania roztworu do infuzji 35 mg | Agalsidasum alfa koncentrat do sporządzania roztworu do infuzji 1mg/ml | Chlorowodorek migalastatu 123 mg | Nusinersen 12 mg/5 ml | Risdiplamum proszek do sporządzania roztworu doustnego 0,75 mg/ml oraz Risdiplamum 5 mg | Omaveloxolonum 50 mg | Esketaminy chlorowodorek w ilości odpowiadającej 28 mg...
This Poland Pharmaceuticals opportunity is one most of your competitors will never see.
How to bid: GlobalGov tracks this tender; it does not accept bids. Submit your response through the issuing agency’s official notice.
Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.
Start a free GlobalGov account| Issuing agency | Instytut Psychiatrii I Neurologii |
|---|
| Country | Poland |
|---|
| Category | Pharmaceuticals |
|---|
| CPV | 33600000 |
|---|
| Published | September 28, 2026 |
|---|
| Procurement stage | Request for Proposal (RFP) |
|---|
| Response due | October 26, 2026 |
|---|
| Status | Open — accepting responses |
|---|
| Original language | Polish — members read it in their own language |
|---|
| Official source | View original notice |
|---|
| Last verified | October 11, 2026 |
|---|
Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.
See every Poland Pharmaceuticals opportunity your competition is missing. Free for 14 days.
Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.
Start Free Trial — No Card RequiredFree 14-day trial · no card required
See who is already competing here →Used by capture teams who win by looking where the big players aren’t.
Get a free Poland Pharmaceuticals intelligence report in your inbox
A personalized report on Poland Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.